Who are moxifloxacin/prednisolone combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moxifloxacin-prednisolone-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

moxifloxacin/prednisolone combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

moxifloxacin/prednisolone combination (moxifloxacin/prednisolone combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic and corticosteroid combination. Area: Ophthalmology.

phase 3 Fluoroquinolone antibiotic and corticosteroid combination DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

moxifloxacin/prednisolone combination (moxifloxacin/prednisolone combination) — Adapt Produtos Oftalmológicos Ltda.. Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
moxifloxacin/prednisolone combination TARGET	moxifloxacin/prednisolone combination	Adapt Produtos Oftalmológicos Ltda.	phase 3	Fluoroquinolone antibiotic and corticosteroid combination	DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic and corticosteroid combination class)

Adapt Produtos Oftalmológicos Ltda. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). moxifloxacin/prednisolone combination — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-prednisolone-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab